INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 41 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $1,514,000 | -12.0% | 1,500,000 | -25.0% | 0.07% | -5.3% |
| Q3 2019 | $1,720,000 | -3.5% | 2,000,000 | 0.0% | 0.08% | +8.6% |
| Q2 2019 | $1,782,000 | -10.2% | 2,000,000 | 0.0% | 0.07% | -15.7% |
| Q1 2019 | $1,984,000 | +7.3% | 2,000,000 | 0.0% | 0.08% | -11.7% |
| Q4 2018 | $1,849,000 | -8.4% | 2,000,000 | 0.0% | 0.09% | +28.8% |
| Q3 2018 | $2,018,000 | +14.8% | 2,000,000 | 0.0% | 0.07% | +19.7% |
| Q2 2018 | $1,758,000 | +8.9% | 2,000,000 | 0.0% | 0.06% | +7.0% |
| Q1 2018 | $1,615,000 | +0.1% | 2,000,000 | 0.0% | 0.06% | +16.3% |
| Q4 2017 | $1,613,000 | +3.4% | 2,000,000 | 0.0% | 0.05% | -25.8% |
| Q3 2017 | $1,560,000 | -20.3% | 2,000,000 | 0.0% | 0.07% | +127.6% |
| Q2 2017 | $1,958,000 | +110.1% | 2,000,000 | +100.0% | 0.03% | +93.3% |
| Q1 2017 | $932,000 | – | 1,000,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Worth Venture Partners, LLC | 5,324,000 | $4,995,000 | 3.78% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 57,791,000 | $53,020,000 | 2.12% |
| DLD Asset Management, LP | 32,500,000 | $30,048,000 | 2.06% |
| Castle Creek Arbitrage, LLC | 4,504,000 | $4,161,000 | 1.43% |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 10,000,000 | $9,372,000 | 0.62% |
| Graham Capital Management, L.P. | 14,636,000 | $13,509,000 | 0.60% |
| OAKTREE CAPITAL MANAGEMENT LP | 64,452,000 | $59,704,000 | 0.54% |
| Context Capital Management, LLC | 1,000,000 | $926,000 | 0.52% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 23,118,000 | $21,341,000 | 0.52% |
| WOLVERINE ASSET MANAGEMENT LLC | 18,583,000 | $17,322,000 | 0.21% |